Post Hoc Subgroup Analysis of ZEUS: Outcome On Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion From a Calcineurin Inhibitor to an Everolimus Based Regimen

被引：1

作者：

Lehner, F. ^{[1
]}

Sommerer, C. ^{[1
]}

Arns, W. ^{[1
]}

Reinke, P. ^{[1
]}

Eisenberger, U. ^{[1
]}

Wuthrich, R. ^{[1
]}

Pressmar, K. ^{[1
]}

Hauser, I. ^{[1
]}

Porstner, M. ^{[2
]}

May, C. ^{[2
]}

Paulus, E. ^{[2
]}

Muehlfeld, A. ^{[1
]}

Suwelack, B. ^{[1
]}

Wolters, H. ^{[1
]}

Witzke, O. ^{[1
]}

Stahl, R. ^{[1
]}

Budde, K. ^{[1
]}

机构：

[1] ZEUS Study Grp, Nurnberg, Germany

[2] Novartis Pharmaceut, Nueremberg, Germany

来源：

TRANSPLANTATION | 2014年 / 98卷

关键词：

D O I：

10.1097/00007890-201407151-02074

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

C1917

引用

页码：613 / 613

页数：1

共 50 条

[21] Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients
Fructuoso, A. Sanchez
Millan, J. C. Ruiz San
Calvo, N.
Rodrigo, E.
Moreno, M. A.
Cotorruelo, J.
Conesa, J.
Gomez-Alamillo, C.
Arias, M.
Barrientos, A.
[J]. TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) : 2148 - 2150
[22] Getting the measure of renal function: Determination of best predicted creatinine in, living-donor kidney renal transplant recipients based on donor kidney function
Giessing, Markus
Liefeldt, Lutz
[J]. TRANSPLANTATION, 2008, 86 (04) : 513 - 514
[23] Renal Function Outcomes in Kidney Transplant Recipients After Conversion to Everolimus-Based Immunosuppression Regimen with CNI Reduction or Elimination
Cataneo-Davila, A.
Zuniga-Varga, J.
Correa-Rotter, R.
Alberu, J.
[J]. TRANSPLANTATION PROCEEDINGS, 2009, 41 (10) : 4138 - 4146
[24] Efficacy and Safety of an Everolimus/Enteric-Coated Mycophenolate Sodium Regimen after Calcineurin Inhibitor Withdrawal in De Novo Renal Transplant Patients: Results of the ZEUS Trial
Pietruck, F.
Becker, T.
Arns, W.
Sommerer, C.
Reinke, P.
Eisenberger, U.
Fischer, W.
Kramer, S.
Budde, K.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 499 - 499
[25] Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients
Hamdy, Ahmed F.
Bakr, Mohamed A.
Ghoneim, Mohamed A.
[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (06): : 1225 - 1232
[26] Improvement of Renal Function After the Switch from a Calcineurin Inhibitor to Everolimus in Liver Transplant Recipients with Chronic Renal Dysfunction
Castroagudin, Javier F.
Molina, Esther
Romero, Rafael
Otero, Esteban
Tome, Santiago
Varo, Evaristo
[J]. LIVER TRANSPLANTATION, 2009, 15 (12) : 1792 - 1797
[27] Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity.
Hotta, K.
Iwahara, N.
Tanabe, T.
Shinohara, N.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 1083 - 1083
[28] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED TACROLIMUS IN LIVING-DONOR LIVER TRANSPLANT RECIPIENTS WITH HEPATOCELLULAR CARCINOMA: SUBGROUP ANALYSIS FROM THE H2307-STUDY (NCT01888432)
Settmacher, U.
Braun, F.
Lopez, P. M.
Kochuparampil, J.
Lieb, S.
[J]. TRANSPLANT INTERNATIONAL, 2017, 30 : 27 - 27
[29] Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study
Budde, Klemens
Rath, Thomas
Sommerer, Claudia
Haller, Hermann
Reinke, Petra
Witzke, Oliver
Suwelack, Barbara
Baeumer, Daniel
May, Christoph
Porstner, Martina
Arns, Wolfgang
[J]. CLINICAL NEPHROLOGY, 2015, 83 (01) : 11 - 21
[30] OUTCOME ON RENAL FUNCTION OF AN EVEROLIMUS BASED THERAPY AFTER CALCINEURIN INHIBITOR WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS: 5 YEAR DATA OF THE APOLLO TRIAL
Rath, T.
Sommerer, C.
Suwelack, B.
Arns, W.
Haller, H.
Reinke, P.
Budde, K.
Baeumer, D.
Porstner, M.
Witzke, O.
[J]. TRANSPLANT INTERNATIONAL, 2014, 27 : 50 - 50

← 1 2 3 4 5 →